Log in

NASDAQ:PSTVPlusTherapeuticsInc . Stock Price, Forecast & News

+0.04 (+1.37 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $2.96
50-Day Range
MA: $2.45
52-Week Range
Now: $2.96
Volume182,792 shs
Average Volume351,801 shs
Market Capitalization$12.65 million
P/E RatioN/A
Dividend YieldN/A
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. It also engages in developing DoxoPLUS, an injectable generic PEGylated liposomal formulation of doxorubicin for the treatment of breast, ovarian, multiple myeloma, and Kaposi's sarcoma cancer. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.04 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:PSTV



Sales & Book Value

Annual Sales$7 million
Book Value$0.31 per share


Net Income$-10,890,000.00
Net Margins-138.13%


Market Cap$12.65 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
+0.04 (+1.37 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSTV News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PlusTherapeuticsInc . (NASDAQ:PSTV) Frequently Asked Questions

How has PlusTherapeuticsInc .'s stock price been impacted by COVID-19 (Coronavirus)?

PlusTherapeuticsInc .'s stock was trading at $1.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSTV shares have increased by 108.5% and is now trading at $2.96.
View which stocks have been most impacted by COVID-19

When is PlusTherapeuticsInc .'s next earnings date?

PlusTherapeuticsInc . is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for PlusTherapeuticsInc .

How were PlusTherapeuticsInc .'s earnings last quarter?

PlusTherapeuticsInc . (NASDAQ:PSTV) issued its earnings results on Monday, August, 10th. The company reported ($0.45) EPS for the quarter, beating the Zacks' consensus estimate of ($0.75) by $0.30.
View PlusTherapeuticsInc .'s earnings history

Has PlusTherapeuticsInc . been receiving favorable news coverage?

News coverage about PSTV stock has been trending very positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PlusTherapeuticsInc . earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about PlusTherapeuticsInc .

Are investors shorting PlusTherapeuticsInc .?

PlusTherapeuticsInc . saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 145,600 shares, a decrease of 21.3% from the June 15th total of 184,900 shares. Based on an average daily volume of 270,500 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.8% of the company's stock are short sold.
View PlusTherapeuticsInc .'s Short Interest

Who are some of PlusTherapeuticsInc .'s key competitors?

What other stocks do shareholders of PlusTherapeuticsInc . own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PlusTherapeuticsInc . investors own include Advanced Micro Devices (AMD), Trevena (TRVN), CymaBay Therapeutics (CBAY), Chimerix (CMRX), Genocea Biosciences (GNCA), Aileron Therapeutics (ALRN), Fulcrum Therapeutics (FULC), Ibio (IBIO), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

Who are PlusTherapeuticsInc .'s key executives?

PlusTherapeuticsInc .'s management team includes the following people:
  • Dr. Marc H. Hedrick, CEO, Pres & Director (Age 56)
  • Mr. Alan Lins, Principal Financial & Accounting Officer, VP of Fin. and Controller
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 58)
  • Mr. Russ Havranek, VP of Global Marketing
  • Mr. Gary S. Titus, Advisor (Age 59)

What is PlusTherapeuticsInc .'s stock symbol?

PlusTherapeuticsInc . trades on the NASDAQ under the ticker symbol "PSTV."

How do I buy shares of PlusTherapeuticsInc .?

Shares of PSTV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PlusTherapeuticsInc .'s stock price today?

One share of PSTV stock can currently be purchased for approximately $2.96.

How big of a company is PlusTherapeuticsInc .?

PlusTherapeuticsInc . has a market capitalization of $12.65 million and generates $7 million in revenue each year. PlusTherapeuticsInc . employs 37 workers across the globe.

What is PlusTherapeuticsInc .'s official website?

The official website for PlusTherapeuticsInc . is www.plustherapeutics.com.

How can I contact PlusTherapeuticsInc .?

PlusTherapeuticsInc .'s mailing address is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 737-255-7194 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.